Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion’s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development.

Diffusion Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $31.5B in funding across 264 round(s). With a team of 11-50 employees, Diffusion Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - Diffusion Pharmaceuticals, raised $3.9M. Discover more about their projects, partnerships, and impact on our platform.